Soleno Therapeutics (SLNO), Thursday announced the pricing of its underwritten public offering of approximately 2.35 million shares of common stock at $85.00 per share, expected to raise about $200 million in gross proceeds.
The offering includes a 30-day option for underwriters to purchase up to an additional 352,941 shares. The closing is anticipated on or around July 11, 2025, pending customary conditions.
Proceeds from the offering will support the commercialization of VYKAT XR, Soleno's FDA-approved therapy for hyperphagia in Prader-Willi syndrome, as well as regulatory and market development efforts in the EU. Additional funds will go toward R&D, general corporate purposes, and potential future acquisitions.
SLNO is currently trading at $84.86, down $3.63 or 4.11 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.